Evolent Health (EVH) Depreciation & Amortization (CF) (2015 - 2026)

Evolent Health's Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $21.6 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 10.4% year-over-year to $21.6 million in Q1 2026; TTM through Mar 2026 was $113.3 million, a 0.37% change from a year earlier, with the FY2025 full-year figure at $115.9 million, down 2.13% from the prior year.
• Depreciation & Amortization (CF) eased to $21.6 million in Q1 2026 per EVH's latest filing, from $45.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $45.0 million in Q4 2025 and bottomed at $15.1 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $29.3 million (2023), against an average of $26.3 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 112.64% in 2023 and dropped 22.53% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $19.8 million in 2022, then soared by 49.65% to $29.6 million in 2023, then dropped by 1.03% to $29.3 million in 2024, then surged by 53.73% to $45.0 million in 2025, then plunged by 52.14% to $21.6 million in 2026.
• Per Business Quant, the three latest EVH Depreciation & Amortization (CF) figures stand at $21.6 million (Q1 2026), $45.0 million (Q4 2025), and $23.6 million (Q3 2025).